Tags

Type your tag names separated by a space and hit enter

Combining computational methods for hit to lead optimization in Mycobacterium tuberculosis drug discovery.
Pharm Res. 2014 Feb; 31(2):414-35.PR

Abstract

PURPOSE

Tuberculosis treatments need to be shorter and overcome drug resistance. Our previous large scale phenotypic high-throughput screening against Mycobacterium tuberculosis (Mtb) has identified 737 active compounds and thousands that are inactive. We have used this data for building computational models as an approach to minimize the number of compounds tested.

METHODS

A cheminformatics clustering approach followed by Bayesian machine learning models (based on publicly available Mtb screening data) was used to illustrate that application of these models for screening set selections can enrich the hit rate.

RESULTS

In order to explore chemical diversity around active cluster scaffolds of the dose-response hits obtained from our previous Mtb screens a set of 1924 commercially available molecules have been selected and evaluated for antitubercular activity and cytotoxicity using Vero, THP-1 and HepG2 cell lines with 4.3%, 4.2% and 2.7% hit rates, respectively. We demonstrate that models incorporating antitubercular and cytotoxicity data in Vero cells can significantly enrich the selection of non-toxic actives compared to random selection. Across all cell lines, the Molecular Libraries Small Molecule Repository (MLSMR) and cytotoxicity model identified ~10% of the hits in the top 1% screened (>10 fold enrichment). We also showed that seven out of nine Mtb active compounds from different academic published studies and eight out of eleven Mtb active compounds from a pharmaceutical screen (GSK) would have been identified by these Bayesian models.

CONCLUSION

Combining clustering and Bayesian models represents a useful strategy for compound prioritization and hit-to lead optimization of antitubercular agents.

Authors+Show Affiliations

Collaborative Drug Discovery, 1633 Bayshore Highway, Suite 342, Burlingame, California, 94010, USA, ekinssean@yahoo.com.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, American Recovery and Reinvestment Act
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24132686

Citation

Ekins, Sean, et al. "Combining Computational Methods for Hit to Lead Optimization in Mycobacterium Tuberculosis Drug Discovery." Pharmaceutical Research, vol. 31, no. 2, 2014, pp. 414-35.
Ekins S, Freundlich JS, Hobrath JV, et al. Combining computational methods for hit to lead optimization in Mycobacterium tuberculosis drug discovery. Pharm Res. 2014;31(2):414-35.
Ekins, S., Freundlich, J. S., Hobrath, J. V., Lucile White, E., & Reynolds, R. C. (2014). Combining computational methods for hit to lead optimization in Mycobacterium tuberculosis drug discovery. Pharmaceutical Research, 31(2), 414-35. https://doi.org/10.1007/s11095-013-1172-7
Ekins S, et al. Combining Computational Methods for Hit to Lead Optimization in Mycobacterium Tuberculosis Drug Discovery. Pharm Res. 2014;31(2):414-35. PubMed PMID: 24132686.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Combining computational methods for hit to lead optimization in Mycobacterium tuberculosis drug discovery. AU - Ekins,Sean, AU - Freundlich,Joel S, AU - Hobrath,Judith V, AU - Lucile White,E, AU - Reynolds,Robert C, Y1 - 2013/10/17/ PY - 2013/05/04/received PY - 2013/07/28/accepted PY - 2013/10/18/entrez PY - 2013/10/18/pubmed PY - 2014/9/10/medline SP - 414 EP - 35 JF - Pharmaceutical research JO - Pharm. Res. VL - 31 IS - 2 N2 - PURPOSE: Tuberculosis treatments need to be shorter and overcome drug resistance. Our previous large scale phenotypic high-throughput screening against Mycobacterium tuberculosis (Mtb) has identified 737 active compounds and thousands that are inactive. We have used this data for building computational models as an approach to minimize the number of compounds tested. METHODS: A cheminformatics clustering approach followed by Bayesian machine learning models (based on publicly available Mtb screening data) was used to illustrate that application of these models for screening set selections can enrich the hit rate. RESULTS: In order to explore chemical diversity around active cluster scaffolds of the dose-response hits obtained from our previous Mtb screens a set of 1924 commercially available molecules have been selected and evaluated for antitubercular activity and cytotoxicity using Vero, THP-1 and HepG2 cell lines with 4.3%, 4.2% and 2.7% hit rates, respectively. We demonstrate that models incorporating antitubercular and cytotoxicity data in Vero cells can significantly enrich the selection of non-toxic actives compared to random selection. Across all cell lines, the Molecular Libraries Small Molecule Repository (MLSMR) and cytotoxicity model identified ~10% of the hits in the top 1% screened (>10 fold enrichment). We also showed that seven out of nine Mtb active compounds from different academic published studies and eight out of eleven Mtb active compounds from a pharmaceutical screen (GSK) would have been identified by these Bayesian models. CONCLUSION: Combining clustering and Bayesian models represents a useful strategy for compound prioritization and hit-to lead optimization of antitubercular agents. SN - 1573-904X UR - https://www.unboundmedicine.com/medline/citation/24132686/Combining_computational_methods_for_hit_to_lead_optimization_in_Mycobacterium_tuberculosis_drug_discovery_ L2 - https://doi.org/10.1007/s11095-013-1172-7 DB - PRIME DP - Unbound Medicine ER -